GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...
GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.
Zacks Investment Research on MSN
GSK's chronic hepatitis B drug meets goals in two late-stage studies
GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational ...
Hepatitis B is a virus that can damage the liver and lead to lifelong health problems. The hepatitis B vaccine prevents short ...
Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.
There has been a lot of public attention surrounding pediatric hepatitis B vaccines recently. Are they safe? Are they ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, ...
Topline data were announced from two phase 3 studies evaluating bepirovirsen for the treatment of chronic hepatitis B.
An advisory panel appointed by Robert F. Kennedy Jr. will vote on delaying the hepatitis B vaccine for newborns. Hepatitis B is highly infectious and incurable. Doctors urge parents to vaccinate ...
The Tuskegee syphilis study stands as one of the greatest moral failures in American medical history, a reminder of what ...
An advisory panel to the CDC voted to stop recommending hepatitis B shots at birth for most newborns. Why doctor says that's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback